ClinicalTrials.gg
RecruitingNCT04939441Updated Nov 12, 2026

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

A Phase 4 interventional study of Tenofovir alafenamide in Chronic Hepatitis B, sponsored by Jidong Jia. Recruiting at 9 sites in China. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Jidong Jia · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.
Updated Nov 12, 2026Now RecruitingResults publication added+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic — 5 open to participants now, 10 under way, 1 of them phase 3. tenofovir alafenamide · Hepatitis B, Chronic.

Planned enrollment
16th of 26
100 · median 124
Started
2021
with 6 others
Phase 4
14 of 26
4 open now
Registered
19th of 26
by date
Lead sponsor
1 of 26
Jidong Jia

Among the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, this one is the 16th largest by planned enrollment, is one of 7 that started in 2021, is one of 14 in phase 4, and was the 19th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tenofovir alafenamide in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven significant fibrosis (METAVIR fibrosis stage ≥ F2). To characterize longitudinal histological changes and assess liver fibrosis regression, the second and third liver biopsies are planned at weeks 96 and 240, respectively. During this study, all subjects will be assessed for laboratory tests, imaging examination at baseline, first 12-week and every 24-week during follow-up.

03

Conditions studied

  • Chronic Hepatitis B

Keywords

  • Chronic Hepatitis B
  • Liver fibrosis, Liver cirrhosis
  • Tenofovir alafenamide
  • fibrosis regression
  • histological changes
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-69 years old (inclusive);
  • (18-30 kg/m2);
  • Chronic virus (HBV) infection, defined as positive serum hepatitis B s-antigen (HBsAg) for more than 6 months; or chronic hepatitis B proven by live ;
  • Not received nucleoside (acid) analogue and/or interferon therapy (treatment-naive);
  • Liver biopsy performed within 6 months before treatment and had readable biopsy slides or agrees to have a biopsy performed prior to baseline;
  • METAVIR fibrosis stage ≥ F2;
  • For patients without cirrhosis (F2/3), HBV DNA levels >2000 IU/mL before treatment; For patients with cirrhosis (F4), HBV DNA >20 IU/mL before treatment;
  • ≤10 before treatment;
  • ≥ 50 mL/min;
  • Agreement not to undertake other HBV systemic antiviral or interferon (IFN) regimens during participation in this study;
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Patients with Child-Turcotte-Pugh(CTP)score ≥ 7;
  • Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or liver transplantation;
  • Patients co-infection with virus (HCV), (HIV), or hepatitis delta virus (HDV), or alcoholic liver diseases, liver disease, genetic liver disease, drug-induced liver injury, non-alcoholic fatty liver disease or other chronic liver diseases;
  • Patients with evidence of hepatocellular carcinoma (HCC) by imaging with or without AFP;
  • Patients with other uncured malignant tumors;
  • Patients with organ or bone marrow transplantation;
  • Patients currently receiving therapy with immunomodulators (eg, , etc.), agents, nephrotoxic agents, or agents susceptible of modifying renal excretion;
  • Patients who are allergic to any component of TAF;
  • Patients who recently or newly started bisphosphate (within 1 month);
  • Patients with active alcohol or drug abuse or history of alcohol or drug abuse (hinder compliance with treatment, or participation in the study or interpretation of results considered by the Investigator);
  • Patients with significant renal, cardiovascular, pulmonary, or neurological disease
  • Males and females of who are unwilling to use an effective method of during the study;
  • Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study;
  • Not suitable for this study identified by researchers.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    TAF group

    TAF \[Vemlidy® 25mg QD\] monotherapy

    Drug: Tenofovir alafenamide

Interventions

  • Subjects will be treated for 240 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy

    Also known as: Vemlidy®

06

What researchers measure

Primary outcomes

  1. Proportion of patients with fibrosis regression

    Fibrosis stage decrease at least 1 point by Ishak score or "Predominantly Regressive" by "Beijing classification"

    Time frame: Week 96 and 240

  2. HBV DNA undetectable rate

    Serum HBV DNA \<20 IU/mL

    Time frame: Week 96

Secondary outcomes

  1. Percentage of liver stiffness decrease >= 30%

    Proportion of patients with liver stiffness decrease \>= 30% from baseline to week 240

    Time frame: Week 48, week 96, week 144, week 192 and week 240

  2. HBV DNA undetectable rate

    HBV DNA undetectable rate at week 24, 48, 72, 144, 192 and 240

    Time frame: Week 24, week 48, week 72, week 144, week 192 and week 240

  3. ALT normalization rate

    Proportion of patients with ALT \<= 1.0xULN

    Time frame: Week 48, week 96, week 144, week 192 and week 240

  4. HBeAg and HBsAg loss and seroconversion rate

    Proportions of patients with HBsAg loss and seroconversion to anti-HBs, and proportions of patients with HBeAg loss and seroconversion to anti-HBe.

    Time frame: Week 48, week 96, week 144 and week 240

  5. Changes in renal function

    Changes of eGFR (estimated Glomerular Filtration rate) from baseline to week 48, 96, 144, 192 and 240.

    Time frame: Week 48, week 96, week 144, week 192 and week 240

  6. Changes of bone mineral density

    Percentage changes in spine BMD and hip BMD from baseline to week 48, 96, 144, 192 and 240

    Time frame: Week 48, week 96, week 144, week 192 and week 240

  7. Incidence of liver-related endpoint events

    liver-related endpoint events: decompensation, HCC, liver transplantation, liver-related death

    Time frame: Week 96 and week 240

07

Study locations

9 of 9 sites recruiting
08

References and documents

Publications

  • Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10. PubMed 23234725 ↗
  • Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13. PubMed 25788199 ↗
  • Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K; GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22. PubMed 28404091 ↗
  • Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. PubMed 28404092 ↗
  • Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Celen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17. PubMed 29756595 ↗

Individual participant data

Plan to share: Undecided — We will consider sharing it after the primary outcome is published.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Dec 2027, 80 months after the start.

Of 46 non-industry phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 83. This study's planned 80 months is above that.

Counting every sponsor, half of 63 studies reached it within 44 months; a quarter within 30 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion May 2024 → Dec 2027 and completion May 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2021
First posted
Jun 25, 2021
StartActual
Apr 20, 2021
Primary completionEst.
Dec 31, 2027was May 2024
CompletionEst.
Dec 31, 2027was May 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 12, 2026
Sites
9 sites added, 7 sites removed
Show 9 added (9 China)
  • Beijing Ditan Hospital, Capital Medical University · Beijing, China
  • The Fifth People's Hospital of Suzhou · Suzhou, China
  • The Ninth Hospital of Nanchang · Nanchang, China
  • Shuguang Hospital · Shanghai, China
  • Huashan Hospital Fudan University · Shanghai, China
  • Ruijin Hospital · Shanghai, China
  • Tianjin Third Central Hospital · Tianjin, China
  • Tianjin Second People's Hospital · Tianjin, China
  • Beijing YouAn Hospital, Capital Medical University · Beijing, China
Show 7 removed
  • Beijing Ditan Hospital, Capital Medical University · Beijing, China
  • Shuguang Hospital · Shanghai, China
  • Huashan Hospital Fudan University · Shanghai, China
  • Ruijin Hospital · Shanghai, China
  • Shanghai East Hospital · Shanghai, China
  • Tianjin Third Central Hospital · Tianjin, China
  • Tianjin Second People's Hospital · Tianjin, China
Nov 12, 2026
Primary completion
May 1, 2024→Dec 31, 2027
Nov 12, 2026
Study completion
May 1, 2025→Dec 31, 2027
Nov 12, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameProportion of patients with fibrosis regressionWeek 96 → Week 96 and 240
Nov 12, 2026
Publications
Results publication added: Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramani… PubMed 23234725 ↗; 1 more
Nov 12, 2026
Secondary outcomes
7 time frame changed, 4 description edited
What changed in the outcomes
  • Time framePercentage of liver stiffness decrease >= 30%Week 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
  • Time frameHBV DNA undetectable rateWeek 24, Week 48 and Week 72 → Week 24, week 48, week 72, week 144, week 192 and week 240
  • Time frameALT normalization rateWeek 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
  • Time frameHBeAg and HBsAg loss and seroconversion rateWeek 48 and Week 96 → Week 48, week 96, week 144 and week 240
  • Time frameChanges in renal functionWeek 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
  • Time frameChanges of bone mineral densityWeek 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
  • Time frameIncidence of liver-related endpoint eventsWeek 96 → Week 96 and week 240
  • DescriptionChanges in renal function: how it is measured was reworded
  • DescriptionChanges of bone mineral density: how it is measured was reworded
  • DescriptionHBV DNA undetectable rate: how it is measured was reworded
  • DescriptionPercentage of liver stiffness decrease >= 30%: how it is measured was reworded
Nov 12, 2026
Contact
Study contact now listed: added j•••@ccmu.edu.cn · •••9246; added z•••@126.com · •••8665. See the current contact
Nov 12, 2026
Sponsor
Collaborators added: The Ninth Hospital of Nanchang·Beijing YouAn Hospital·The Fifth People's Hospital of Suzhou; collaborators removed: The Sixth Peoples Hospital of Zhengzhou·Shanghai East Hospital
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Recruiting
    Publications Results publication added: Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramani… PubMed 23234725 ↗; 1 more
    9 sites added, 7 sites removed
    Show 9 added (9 China)
    • Beijing Ditan Hospital, Capital Medical University · Beijing, China
    • The Fifth People's Hospital of Suzhou · Suzhou, China
    • The Ninth Hospital of Nanchang · Nanchang, China
    • Shuguang Hospital · Shanghai, China
    • Huashan Hospital Fudan University · Shanghai, China
    • Ruijin Hospital · Shanghai, China
    • Tianjin Third Central Hospital · Tianjin, China
    • Tianjin Second People's Hospital · Tianjin, China
    • Beijing YouAn Hospital, Capital Medical University · Beijing, China
    Show 7 removed
    • Beijing Ditan Hospital, Capital Medical University · Beijing, China
    • Shuguang Hospital · Shanghai, China
    • Huashan Hospital Fudan University · Shanghai, China
    • Ruijin Hospital · Shanghai, China
    • Shanghai East Hospital · Shanghai, China
    • Tianjin Third Central Hospital · Tianjin, China
    • Tianjin Second People's Hospital · Tianjin, China
    Primary completion May 1, 2024→Dec 31, 2027
    Study completion May 1, 2025→Dec 31, 2027
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameProportion of patients with fibrosis regressionWeek 96 → Week 96 and 240
    Secondary outcomes 7 time frame changed, 4 description edited
    What changed in the outcomes
    • Time framePercentage of liver stiffness decrease >= 30%Week 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
    • Time frameHBV DNA undetectable rateWeek 24, Week 48 and Week 72 → Week 24, week 48, week 72, week 144, week 192 and week 240
    • Time frameALT normalization rateWeek 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
    • Time frameHBeAg and HBsAg loss and seroconversion rateWeek 48 and Week 96 → Week 48, week 96, week 144 and week 240
    • Time frameChanges in renal functionWeek 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
    • Time frameChanges of bone mineral densityWeek 48 and Week 96 → Week 48, week 96, week 144, week 192 and week 240
    • Time frameIncidence of liver-related endpoint eventsWeek 96 → Week 96 and week 240
    • DescriptionChanges in renal function: how it is measured was reworded
    • DescriptionChanges of bone mineral density: how it is measured was reworded
    • DescriptionHBV DNA undetectable rate: how it is measured was reworded
    • DescriptionPercentage of liver stiffness decrease >= 30%: how it is measured was reworded
    Sponsor Collaborators added: The Ninth Hospital of Nanchang·Beijing YouAn Hospital·The Fifth People's Hospital of Suzhou; collaborators removed: The Sixth Peoples Hospital of Zhengzhou·Shanghai East Hospital
    Contact Study contact now listed: added j•••@ccmu.edu.cn · •••9246; added z•••@126.com · •••8665. See the current contact
    + 7 other changes: identifiers, verification date, description, conditions, design details, arm descriptions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04939441
Lead sponsor
Jidong Jia
Collaborators
Beijing Ditan Hospital, ShuGuang Hospital, Huashan Hospital, Tianjin Second People's Hospital, Ruijin Hospital, Tianjin Third Central Hospital, The Ninth Hospital of Nanchang, Beijing YouAn Hospital, The Fifth People's Hospital of Suzhou
Responsible party
Jidong Jia (Director of Liver Research Center, Beijing Friendship Hospital) — Sponsor-investigator
First posted
Jun 25, 2021
Start date
Apr 20, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Jidong Jia
Contact
jia_jd@ccmu.edu.cn
86-010-63139246
Jialing Zhou
Contact
zhoujialing11@126.com
86-010-63138665
Jidong Jia
principal investigator · Beijing Friendship Hospital, Capital Medical Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion